Oral small molecule GLP-1 receptor agonist
VCT220 120 mg tablet once daily
VCT220_PO_120MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.48 (0.11 to 41.71) | 0.35 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.88 (0.06 to 9.69) | 0.66 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.51 (2.32 to 15.17) | 0.30 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.21 (1.53 to 12.46) | 0.50 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.08 (0.71 to 6.46) | 0.46 |